Novartis appeals IP Australia decision invalidating MS drug patent
Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
